Estimating Cost Savings from Early Cancer Diagnosis

Zura Kakushadze, Rakesh Raghubanshi and Willie Yu

Papers from arXiv.org

Abstract: We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test.

Date: 2017-08, Revised 2019-04
New Economics Papers: this item is included in nep-hea
References: View complete reference list from CitEc
Citations:

Published in Data 2(3) (2017) 30

Downloads: (external link)
http://arxiv.org/pdf/1709.01484 Latest version (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:arx:papers:1709.01484

Access Statistics for this paper

More papers in Papers from arXiv.org
Bibliographic data for series maintained by arXiv administrators ().